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Background: Indigenous adults residing in the Northern Territory of Australia experience elevated rates of
invasive pneumococcal disease despite the routine use of 23-valent pneumococcal polysaccharide vac-
cine (23vPPV). We hypothesised that the limited protection from 23vPPV may be due to hyporesponsive-
ness as a result of vaccine failure from repeated vaccination. To explore this possibility, we evaluated the
immune response to a first and second dose of 23vPPV in Indigenous adults and a first dose of 23vPPV in
non-Indigenous adults.
Methods: Serotype-specific IgG was measured by ELISA for all 23 vaccine serotypes at baseline and at one
month post-vaccination. Individuals were considered to have an adequate immune response if paired
sera demonstrated either: a four-fold rise in antibody concentration; a two-fold rise if the post vaccina-
tion antibody was >1.3 lg/ml but <4.0 lg/ml; or a post-vaccination antibody concentration >4.0 lg/ml
for at least half of the serotypes tested (12/23). Our per-protocol analysis included the comparison of out-
comes for three groups: Indigenous adults receiving a second 23vPPV dose (N = 20) and Indigenous
(N = 60) and non-Indigenous adults (N = 25) receiving their first 23vPPV dose.
Results: All non-Indigenous adults receiving a first dose of 23vPPV mounted an adequate immune
response (25/25). There was no significant difference in the proportion of individuals with an adequate
response using our definition (primary endpoint), with 88% of Indigenous adults mounted an adequate
response following first dose 23vPPV (53/60) compared to 70% having an adequate response following
a second dose of 23vPPV (14/20; p = 0.05). The risk difference between Indigenous participants receiving
first dose compared to non-Indigenous participants receiving first dose was significant when comparing a
response threshold of at least 70% (27%, 95% CI: 43% to 11%; p = 0.01) and 90% (38%, 95% CI: 60%
to 16%; p = 0.006) of serotypes with a positive response.
Conclusion: Indigenous participants demonstrated a poorer response to a first dose 23vPPV compared to
their non-Indigenous counterparts, with lower IgG following a second 23vPPV dose. These findings high-
light the critical need to evaluate the efficacy of future pneumococcal vaccine programs in the Australian
Indigenous populations that recommend repeated doses of 23vPPV.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Indigenous adults in the Northern Territory of Australia suffer
one of the highest reported rates of pneumococcal disease world-
wide, exceeding 10-fold higher than non-Indigenous adults [1]. A
http://dx.doi.org/10.1016/j.vaccine.2017.04.040
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unique schedule of repeated vaccination with the 23-valent pneu-
mococcal polysaccharide vaccine (23vPPV) is recommended for
Indigenous adults residing in the Northern Territory (NT) of Aus-
tralia owing to their elevated rates of pneumococcal disease
[2,3]. Since 1995, 23vPPV has been recommended for all Indige-
nous Australian adults aged 50 years and over and for all Aus-
tralians aged 15–49 years with medical risk factors. As a regional
initiative in 2000, this was expanded to include all Indigenous
adults in the NT aged 15 years and over [4]. Non-Indigenous adults
without medical risk factors receive their first dose at 65 years of
age. Revaccination was initially recommended every five years,
but since 2003, a maximum of three lifetime doses has been rec-
ommended for Indigenous adolescents and adults and non-
Indigenous adults with medical risk factors: a second dose five
years after the first dose and then a third dose ten years after the
second, or at age 50 years, whichever is later [5].
This unique 23vPPV regimen has not been associated with a
reduction in invasive pneumococcal disease (IPD) incidence within
Indigenous adults residing in the NT, although vaccination cover-
age has been generally low [1]. While there is some evidence of
an adequate immunological response to revaccination, no data
are available from randomised controlled trials determining clini-
cal efficacy [6–9]. Immune hyporesponsiveness, associated with
the production of attenuated serotype-specific IgG responses to
vaccine serotypes, has been suggested to result following repeated
polysaccharide immunisation and has been demonstrated follow-
ing 23vPPV in Fijian children [10], although this was no longer
apparent by 5 years of age [11]. To investigate the possibility that
hyporesponsiveness following repeat vaccination may be one fac-
tor contributing to persistently high rates of pneumococcal disease
in Indigenous adults, we compared the immune response following
a second dose of 23vPPV in Indigenous Australians with the
response following a first dose in both Indigenous and non-
Indigenous Australians.
2. Ethical approval
The study was approved by the Human Research Ethics Com-
mittee of the NT Department of Health and the Menzies School
of Health Research (06/57), and includes assessment by the Aborig-
inal Ethics Sub-Committee.
3. Materials and methods
3.1. Study population
Potential participants were recruited from remote Aboriginal
communities in the Top End of the NT, Darwin (the NT capital city),
and the Darwin Correctional Centre. Participants were recruited
between 10th November 2010–29th November 2011 when the
Therapeutic Goods Administration suspended use of 23vPPV owing
to reports of increased adverse reactions following repeated doses
of 23vPPV. Recruitment then commenced again between 5th
December 2012–7th February 2013. The informed consent process
included a discussion using a pictorial flip chart and plain language
participant information sheet explaining the study requirements,
risks and benefits. Potential participants were only recruited when
the study staff felt the requirements were understood. Eligible par-
ticipants were adults aged 15–59 years, due for a first or second
dose of 23vPPV as per the recommended NT schedule (Indigenous
adults) or for whom the vaccine was not otherwise contra-
indicated (non-Indigenous adults). Exclusion criteria included
pregnancy or known allergy to any component within 23vPPV.
Blood was collected immediately prior to and one month after
23vPPV vaccination for the following groups: Group 1; first dose
23vPPV, Indigenous adults; Group 2; second dose 23vPPV, Indige-
nous adults; and Group 3; first dose 23vPPV, non-Indigenous
adults. Life course vaccination status was confirmed with the NT
adult vaccination database.
3.2. Measurement of pneumococcal antibody response
Serotype-specific IgG levels for each of the 23 serotypes con-
tained in 23vPPV were measured by a modified WHO ELISA pub-
lished previously [12,13].
3.3. Definition of adequate response
We defined a priori an adequate response to 23vPPV in this pop-
ulation using a combination of internationally standardised criteria
developed for evaluation of immune deficiency [14,15] as well as
taking into consideration study population characteristics such as
age and chronic illness. An ‘adequate’ immune response in paired
pre- and post-vaccination sera was defined for each vaccine sero-
type as either:
 4-fold rise in serotype-specific antibody titre; OR
 2-fold rise in serotype-specific antibody titre if the post vacci-
nation concentration of pneumococcal polysaccharide serotype
specific antibody was 1.3 lg/ml and 4.0 lg/ml; OR
 a post vaccination pneumococcal polysaccharide serotype
specific antibody concentration >4.0 lg/ml regardless of the
fold-rise in titre from pre-vaccination concentration.
An overall positive response to 23vPPV required an adequate
response to at least 50% (12 serotypes) of the 23 vaccine serotypes.
Comparison of the proportion of participants with an adequate
response to 70% (16 serotypes) of vaccine serotypes was also
done according to current AAAAI guidelines for adults [16]. All
other responses were defined as an inadequate immune response.
3.4. Statistical analysis
Our primary outcome was the comparison of the immune
response between first and second dose Indigenous adult recipi-
ents, for which our intended sample size was 120 participants
per group. We assumed 85% of Indigenous adults receiving a first
23vPPV dose would have an adequate immune response thus pro-
viding 93% power (alpha 0.05) to detect an adequate immune
response in 65% of second dose recipients. We did not adjust
for re-use of the control group (Group 1) in comparisons of the
immune response with the non-Indigenous first dose recipients
(Group 3).
Pearson’s Chi-squared test was used to compare the proportion
of participants with an adequate immune response between
Indigenous participants receiving first dose and second dose
23vPPV (Groups 1 and 2) as the primary analysis, and between
Indigenous and non-Indigenous participants receiving first dose
23vPPV (Groups 1 and 3) as a secondary analysis.
Geometric Mean Concentrations (GMCs) with 95% Confidence
Intervals (CIs) for serotype-specific IgG levels were used to
compared the pre- and post-vaccination response using a Student’s
t-test for Groups 1 v 2 and Groups 1 v 3. A p-value < 0.05 was con-
sidered significant.
4. Results
A total of 60 first-dose Indigenous participants, 20 s-dose
Indigenous participants and 25 first-dose non-Indigenous partici-
pants were included in the final analysis. A further 21 participants
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were excluded from the final analysis: six (from Group 1) did not
have follow-up blood collected and 15 (13 from Group 1 and two
from Group 2) had follow-up blood collected outside the study
window of 25–35 days (range 23–97 days). Overall, we did not
achieve our intended sample size and were underpowered for
the primary analysis.
Table 1 shows the participant characteristics across the groups.
Indigenous participants were more likely to be male, and had a
wider age range than non-Indigenous participants. Indigenous par-
ticipants had higher rates of self-reported chronic illness (such as
diabetes) (23%) compared to non-Indigenous participants (16%),
especially in the second dose group (50%). Self-reported serious
medical conditions (such as kidney disease, rheumatic heart dis-
ease, bronchiectasis) were similar between Indigenous participants
in Groups 1 (12%) and 2 (10%) while non-Indigenous participants
had no serious medical condition reported. The mean time elapsed
between receiving the first and second dose of 23vPPV was 8 years
and 9 months for second dose recipients.
4.1. Poorer adequate response to 23vPPV among Indigenous
participants compared to non-Indigenous participants
Adequate immune responses following 23vPPV were found for
88% (n = 53/60) of Indigenous first-dose recipients compared to
70% (n = 14/20) of Indigenous second-dose recipients and 100%
(n = 25) of non-Indigenous first-dose recipients (Table 2). Although
18% more Indigenous participants receiving a first dose of 23vPPV
met the a priori criteria for an adequate immune response com-
pared to a second dose 23vPPV, this was not statistically significant
(p = 0.05, 95% CI 3% to 40%). Similarly the 12% risk difference
between Indigenous and non-Indigenous first dose participants
was not statistically significant (p = 0.07, 95% CI 20% to 4%;
Table 3).
Considering each aspect of the a priori criteria for an adequate
immune response to 12 (50%) serotypes, a 4-fold rise in antibody
concentration was found amongst 52% of Indigenous first-dose
recipients whilst 47% had post vaccination antibody concentra-
tions beyond the 4.0 lg/ml threshold. Fewer second-dose partici-
pants met the criteria of a 4-fold rise (20%) or the 4.0 lg/ml
threshold (50%). In contrast, almost all non-Indigenous partici-
pants had a 4-fold rise (96%) or a post vaccination titre >4.0 lg/
ml (84%). The difference in the proportion of participants with a
4-fold rise in antibody concentration was statistically significant
for each study group (p < 0.05). Only one participant (Indigenous
first-dose) was classified as having an adequate immune response
on the basis of a 2-fold rise when the post vaccination antibody
concentration was between 1.3 and 4.0 lg/ml (Table 2). As shown
in Fig. 1, non-Indigenous first-dose participants had a median ade-
quate response to 21/23 serotypes, which was significantly higher
than for Indigenous first-dose participants response to a median
18/23 serotypes (p = 0.0003). Indigenous second-dose participants
responded lowest to 15 serotypes but this was not significantly dif-
ferent than 1st dose Indigenous participants.
We also considered the proportion of participants in each group
with an adequate response to varying ‘thresholds’ using three cut-
offs for the number of serotypes: 12 (50% of serotypes), 16
(70%) and 21 (90%) as a post hoc analysis (Table 3). These results
show a similar pattern, where an adequate immune response was
highest among non-Indigenous first-dose participants for all
thresholds, with 60% producing an adequate response to 21 ser-
otypes, followed by Indigenous first-dose and Indigenous second-
dose participants (22% and 15%, respectively). Using these higher
thresholds, the absolute difference in the proportions of adequate
responders was 5% for Indigenous first- versus second-dose partic-
ipants for 16 serotypes (95% CI 20% to 30%, p = 0.69) and 7% for
21 serotypes (95% CI 12% to 25%, p = 0.52). In contrast, the
differential was substantially higher when Indigenous first-dose
participants were compared with non-Indigenous first-dose partic-
ipants: absolute difference was 27% for 16 serotypes (95% CI
43% to 11%, p = 0.01) and 38% for 21 serotypes (95% CI 60%
to 16%, p = 0.006). This suggests that while repeat 23vPPV among
Indigenous participants did not appear to significantly reduce
pneumococcal antibody levels, Indigenous participants had lower
responses to a single 23vPPV dose than non-Indigenous
participants.
We conducted secondary post hoc analyses where we included
participants who had initially been excluded because their post-
vaccination blood collection was outside the study window. This
increased the number of participants to: 73 Indigenous adults
receiving their first 23vPPV dose (increase = 13); 22 Indigenous
adults receiving a second 23vPPV dose (increase = 2); and 25
Table 1
Demographic characteristics of study participants.
Indigenous 1st
dose (n = 60)
Indigenous 2nd
dose (n = 20)
Non-Indigenous
1st dose (n = 25)
Days post-
vaccination
mean (range)
29 (25–35) 28 (25–30) 29 (25–35)
Age mean (range) 34 (16–59) 41 (26–59) 32 (16–41)
Proportion malea 34 (57%) 18 (90%) 8 (32%)
Chronic illnessa 8 (13%) 10 (50%) 4 (16%)
Serious medical
condition
7 (12%) 2 (10%) 0 (0%)
a Difference between groups significantly different p < 0.05
Table 2
Proportion of participants achieving adequate response following 23vPPV.
Overall adequate response
(any)
4-fold rise 2-fold rise and [IgG]
1.3 and 4.0 lg/ml
Post-vaccination 4.0 lg/ml
Group 12 serotypes
(%)
Median
number
of
serotypes
12 serotypes
(%)
Median
number
of
serotypes
12 serotypes
(%)
Median
number
of
serotypes
12 serotypes
(%)
Median
number
of
serotypes
Indigenous 1st dose (n = 60) 53 (88%) 18 31 (52%) 12 1 (2%) 5 28 (47%) 11
Indigenous 2nd dose (n = 20) 14 (70%) 16 2 (20%) 12 0 (0%) 3 10 (50%) 6
Non-Indigenous 1st dose
(n = 25)
25 (100%) 21 24 (96%) 14 0 (0%) 5 21 (84%) 17
Indigenous 1st vs 2nd dose 18% (3 to 40%) 42% (23 to 60%) 2% (2 to 5%) 3% (29 to 22%)
p-value 0.05 0.001 0.56 0.796
Indigenous vs non-Indigenous
1st dose
12% (20 to 4%) 44% (59 to 30%) 2% (2 to 5%) 37% (56 to 18%)
p-value 0.07 0.0001 0.516 0.002
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non-Indigenous adults receiving their first 23vPPV dose (no
change). Under this scenario, the results remained similar with
no significant difference in the proportion of individuals with an
adequate response using our primary endpoint: 89% of Indigenous
adults mounted an adequate response following first dose 23vPPV
(65/73) compared to 73% having an adequate response following a
second dose of 23vPPV (16/22; p = 0.058).
4.2. Effect of age and gender on response to 23vPPV
We stratified the groups based on age and gender, including the
15 participants who had delayed post-vaccination blood collection.
No difference in the proportion of individuals with an adequate
response using any of the criteria was observed when comparing
Indigenous and non-Indigenous participants receiving a first dose
of 23vPPV, or between Indigenous participants given a first or sec-
ond dose of 23vPPV (Table 4). However, for participants 41 years
of age (oldest age in the non-Indigenous group), there was a signif-
icant difference in the median number of serotypes responded to
between first-dose Indigenous (18 serotypes) and non-Indigenous
participants only (21 serotypes, p = 0.0001; Fig. 3). For participants
>41 years old, Indigenous first dose recipients responded to a sig-
nificantly higher number of serotypes (20) compared to Indigenous
second dose recipients (15; p < 0.0019). There were no non-
Indigenous participants >41 years of age so we could not compare
with the other Indigenous groups.
A significantly lower proportion of males had an adequate
response in the second dose Indigenous group (68%) compared to
first dose Indigenous recipients (95%, p = 0.0053; Table 4). No dif-
ferences were found for males or females for all other comparisons.
Similarly, male Indigenous second dose recipients responded with
a significantly lower median number of serotypes (16) compared
to Indigenous first dose recipients (19; p = 0.037; Fig. 3). For female
participants, Indigenous first dose recipients responded to a signif-
icantly lower median number of serotypes (18) compared to non-
Indigenous participants (21; p = 0.0001).
Table 4
Proportion of participants achieving adequate response following 23vPPV; by age and
gender (including participants with delayed blood collection, n = 120).
Overall adequate response (any)
Group 12 serotypes (%) Median number
of serotypes
Age
Indigenous 1st dose
41 years (N = 58) 52 (90) 17
>41 years (N = 15) 13 (87) 18
Indigenous 2nd dose
41 years (N = 12) 10 (83) 18
>41 years (N = 10) 6 (60) 12
Non-Indigenous 1st dose
41 years (N = 25) 25 (100) 20
>41 years (N = 0) – –
Indigenous 1st vs 2nd dose p-value
41 years 0.53
>41 years 0.13
Indigenous vs non-Indigenous 1st dose p-value
41 years 0.095
>41 years NA
Gender
Indigenous 1st dose
Male (N = 40) 38 (95) 18
Female (N = 33) 27 (82) 16
Indigenous 2nd dose
Male (N = 19) 13 (68) 15
Female (N = 3) 3 (100) 18
Non-Indigenous 1st dose
Male (N = 7) 7 (100) 20
Female (N = 18) 18 (100) 21
Indigenous 1st vs 2nd dose p-value
Male 0.005
0.42
Female
Indigenous vs non-Indigenous 1st dose p-value
Male 0.545
Female 0.054
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Fig. 1. Number of serotypes with an adequate immune response for Indigenous 1st
or 2nd dose 23vPPV recipients and non-Indigenous 1st dose recipients. Each data
point represents one member of the study group; the solid line represents the
median.
Table 3
Participants with an adequate immune response according to various thresholds.
Participants with adequate response to
Group 12 serotypes 16 serotypes 21 serotypes
Indigenous 1st dose (n = 60) 53 (88%) 39 (65%) 13 (22%)
Indigenous 2nd dose (n = 20) 14 (70%) 12 (60%) 3 (15%)
Non-Indigenous 1st dose (n = 25) 25 (100%) 23 (92%) 15 (60%)
Indigenous 1st vs 2nd dose
Risk difference (95% CI) 18% (3 to 40%) 5% (20% to 30%) 7% (12% to 25%)
p-value 0.05 0.69 0.52
Indigenous vs non-Indigenous 1st dose
Risk difference (95% CI) 12% (20 to 4%) 27% (43% to 11%) 38% (60% to 16%)
p-value 0.07 0.01 0.006
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4.3. Vaccine failures
We classified inadequate vaccine response by serotype as a sec-
ondary analysis, showing the proportion of participants who failed
to meet the definition of an adequate immune response for the
specific serotype, referred to here as ‘‘vaccine failure”. Whilst not-
ing that numbers were small, and acknowledging that failure to
achieve the pre-specified immune response may not mean that
the vaccine will fail to protect an individual from disease, we found
the proportion of vaccine failures amongst Indigenous first-dose
recipients compared to Indigenous second-dose participants was
higher for all but seven of the 23 serotypes (Fig. 2). Serotype 3
was the most common serotype for which Indigenous participants
failed to mount an adequate immune response (60% and 85% of
participants in Groups 1 and 2, respectively) while for non-
Indigenous participants, vaccine failures were highest for sero-
types 14 and 19F (both 20%) compared to Indigenous 1st dose
(5% and 14%, respectively) and 2nd dose (19% and 9%, respectively)
recipients.
4.4. Absolute levels of serotype-specific IgG were similar across all
groups
Baseline serotype-specific IgG geometric mean concentrations
(GMCs) were similar across Indigenous and non-Indigenous partic-
ipants who had not yet received 23vPPV (Table 5). As expected,
Indigenous second-dose participants had higher baseline IgG levels
for most 23vPPV serotypes. Following 23vPPV, both Indigenous
and non-Indigenous groups receiving their first dose had higher
post-vaccination serotype-specific IgG levels for a majority of ser-
otypes than participants in the second-dose group. Serotype-
specific IgG was significantly higher in Indigenous first-dose com-
pared to Indigenous second-dose groups only for serotype 8
(p = 0.02). Non-Indigenous first-dose participants achieved higher
serotype-specific IgG than Indigenous first-dose participants for
most serotypes, although Indigenous first-dose participants had
significantly higher IgG levels for serotypes 19A (p = 0.003), 22F
(p = 0.002) and 23F (p = 0.009). Moreover, Indigenous participants
receiving their second dose had the smallest post-vaccination
fold-difference across all serotypes (except serotype 12F; Table 5),
most likely due to the higher baseline levels of serotype-specific
IgG. Non-Indigenous first dose participants had the highest fold-
difference across all serotypes apart from 19F and 33F, where
Indigenous first-dose participants had a higher fold rise.
5. Discussion
This is the first study to compare the immune response of Aus-
tralian Indigenous adults receiving a first or second dose of 23vPPV
with non-Indigenous Australians. Despite our small sample size,
our study highlights a serious concern in relation to the immune
response to 23vPPV among Indigenous Australians. Our findings
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suggest that Indigenous participants have a poorer response to
23vPPV compared to their non-Indigenous counterparts, while
Indigenous adults receiving a second dose of 23vPPV produced a
poorer immune response when compared to Indigenous adults
receiving the vaccine for the first time. As this is the first study
to be conducted in this setting, we may have been overly conserva-
tive in our a priori definition that an adequate response should
include at least 50% of the serotypes contained within the 23vPPV.
As a post hoc analysis, we found that setting the benchmark of an
adequate response to 70% (16) of the 23vPPV serotypes (as per
AAAAI guidelines for immunodeficiency) or 90% (21) both
showed Indigenous first-dose recipients had poorer immunological
responses than non-Indigenous first dose 23vPPV recipients.
The effect of 23vPPV on the immune response in children and
adults, especially following a repeat doses, has yielded conflicting
data [6–8,17]. Some of these studies used pooled immune response
data within participant groups for comparison rather than individ-
ual level data, making the results difficult to compare. In the Alas-
kan study, high rates of chronic illness were also observed but with
much lower rates of invasive pneumococcal disease than our study
population [6]. Lower antibody concentrations in our population
[18] suggest that it may be the failure to produce adequate
antibody following vaccination as the key factor in the continued
susceptibility to disease (and failure to observe a reduction in rates
of invasive pneumococcal disease) compared with those in the
Alaskan study.
Furthermore, the non-randomised nature for some of these
studies make interpretation of the results difficult. In a recent
study in Fiji, we found that while hyporesponsiveness was
detected in 23vPPV-vaccinated children after a small challenge
dose of 23vPPV (20% dose) at 18 months of age, their immune sta-
tus had normalised in response to a PCV13 booster dose by 5 years
of age [11]. In the current study, despite the mean time since pre-
vious 23vPPV among Indigenous participants being 8 years and
nine months, there was still a trend towards reduced responsive-
ness, although not significant (p = 0.05), suggesting a residual
impact of the first 23vPPV dose. Although repeat 23vPPV among
Indigenous participants yielded a slightly poorer response
compared to first time vaccinees, the difference in response was
greatest between Indigenous and non-Indigenous participants.
Nasopharyngeal carriage of pneumococcus at the time of vaccina-
tion is known to induce poorer antibody and OPA levels, and is typ-
ically higher among Indigenous compared to non-Indigenous
Australians. A study in Indigenous adults in the Northern Territory
of Australia found pneumococcal nasopharyngeal carriage in 26%
[19] of adults, and may be one reason for the reduced response
level among Indigenous adults. Furthermore, 23vPPV has little
impact on pneumococcal vaccine-type carriage [20], likely con-
tributing to the suboptimal impact on IPD in this population.
Non-response to some pneumococcal serotypes within individ-
uals [21,22] has been documented previously. Differential immune
responses across ethnic groups has also been demonstrated, as
well as across serotypes [23]. Furthermore, individuals with
chronic illness (which were over-represented in our second dose
Indigenous participants) are unlikely to achieve the same level of
protective efficacy of 23vPPV as do healthy adults [18]. We were
unable to adjust for the level of chronic illness in our study due
to small sample size. Nevertheless, our data supports these find-
ings and may provide some explanation as to the failure in demon-
strating a reduction in the high rates of pneumococcal disease
experienced throughout life in our study population despite
increasing coverage with 23vPPV [1]. Our results suggest that
intrinsic genetic differences between Indigenous and non-
Indigenous populations may affect immune responsiveness to
23vPPV, although this needs to be explored in more detail. It is
known that the response to influenza vaccine is lower among
Indigenous adults due to differential expression in certain HLA
genes [24]. While we were unable to rule out other immune
response defects in our study population, measurement of func-
tional immunity by opsonophagocytosis and numbers of
serotype-specific memory B cells may provide further insights into
the mechanisms for the reduced response among Indigenous Aus-
tralians adults.
Response to vaccines is known to be influenced by age and gen-
der. In our study, non-Indigenous participants of young age
(41 years of age) and being female had the highest response to
23vPPV compared to Indigenous first dose recipients while older
(>41 years) male Indigenous first dose participants had higher
responses compared to their second dose counterparts. This is
likely due to the overall increased co-morbidities observed in
Table 5
Serotype-specific IgG geometric mean concentration (95% confidence intervals) pre and post 23vPPV vaccination, by participant group.
Indigenous 1st dose (n = 60) Indigenous 2nd dose (n = 20) Non-Indigenous 1st dose (n = 25)
Serotype Pre Post FRa Pre Post FR Pre Post FR
1 0.47 (0.37,0.60) 2.57 (1.85,3.56) 10.2 1.21 (0.74,2.00) 2.63 (1.46,4.71) 3.4 0.37 (0.27,0.52) 8.39 (5.06,13.92) 38.1
2 0.65 (0.50,0.85) 4.46 (3.12,6.36) 11.5 1.56 (1.16,2.09) 3.43 (2.11,5.56) 4.7 0.95 (0.65,1.40) 14.79 (8.53,25.63) 25.3
3 0.66 (0.53,0.82) 1.50 (1.14,1.97) 3.1 0.63 (0.42,0.93) 1.14 (0.71,1.83) 2.3 0.71 (0.47,1.08) 3.14 (2.04,4.84) 7.3
4 0.30 (0.23,0.38) 1.08 (0.79,1.49) 5.6 0.81 (0.46,1.45) 1.53 (0.81,2.90) 2.5 0.24 (0.15,0.38) 2.10 (1.43,3.08) 14.7
5 0.77 (0.61,0.96) 4.63 (3.49,6.15) 12.4 1.33 (0.77,2.33) 3.55 (1.74,7.24) 4.6 0.55 (0.40,0.75) 5.83 (3.58,9.51) 16.0
6B 0.86 (0.65,1.13) 4.19 (2.89,6.09) 9.3 1.43 (0.81,2.54) 2.98 (1.60,5.57) 3.5 0.42 (0.31,0.58) 2.82 (1.71,4.67) 12.2
7F 1.00 (0.80,1.25) 3.82 (2.89,5.03) 8.2 1.21 (0.80,1.85) 3.44 (2.14,5.53) 3.7 0.50 (0.33,0.76) 9.47 (6.43,13.94) 26.4
8 0.74 (0.54,1.01) 4.74 (3.54,6.34) 14.9 1.10 (0.75,1.63) 2.56 (1.49,4.40) 2.7 0.50 (0.32,0.79) 10.87 (6.35,18.61) 36.4
9N 0.74 (0.57,0.96) 4.19 (3.13,5.61) 10.8 1.83 (1.12,2.99) 4.93 (2.75,8.82) 3.8 0.47 (0.29,0.74) 6.81 (4.75,9.76) 25.3
9V 0.78 (0.62,0.98) 3.42 (2.60,4.51) 7.5 1.19 (0.67,2.10) 3.01 (1.63,5.59) 4.8 0.61 (0.44,0.86) 5.02 (3.58,7.03) 11.8
10A 1.19 (0.96,1.49) 3.05 (2.35,3.94) 3.7 1.36 (0.81,2.28) 3.01 (1.69,5.36) 3.2 0.67 (0.48,0.94) 2.85 (1.90,4.28) 5.6
11A 0.97 (0.75,1.26) 3.14 (2.45,4.02) 6.9 0.86 (0.57,1.29) 2.39 (1.46,3.92) 4.5 1.17 (0.67,2.06) 5.03 (3.25,7.79) 8.7
12F 0.25 (0.20,0.31) 0.83 (0.62,1.13) 7.9 0.36 (0.23,0.56) 1.13 (0.66,1.94) 8.5 0.13 (0.09,0.18) 1.60 (0.99,2.59) 18.4
14 2.52 (1.69,3.76) 14.02 (10.11,19.44) 13.2 9.17 (5.29,15.89) 16.07 (9.47,27.26) 11.2 1.00 (0.54,1.86) 7.64 (3.75,15.56) 13.3
15B 1.70 (1.29,2.24) 8.02 (5.88,10.95) 7.6 4.03 (2.46,6.60) 10.07 (6.12,16.56) 5.1 1.25 (0.76,2.07) 10.01 (6.43,15.57) 12.9
17F 0.59 (0.47,0.74) 3.36 (2.40,4.72) 11.4 1.51 (1.01,2.26) 4.70 (3.29,6.70) 5.0 0.45 (0.32,0.63) 8.20 (5.78,11.65) 24.0
18C 0.92 (0.69,1.22) 4.60 (3.50,6.06) 8.1 1.14 (0.68,1.90) 2.91 (1.65,5.13) 4.5 0.59 (0.39,0.89) 7.76 (5.30,11.37) 20.5
19A 7.31 (5.87,9.10) 10.51 (8.30,13.31) 2.0 5.35 (3.22,8.89) 7.92 (4.75,13.22) 1.9 2.71 (1.94,3.79) 6.86 (4.69,10.05) 3.7
19F 2.16 (1.70,2.75) 7.89 (5.85,10.63) 7.1 4.83 (3.03,7.68) 9.00 (5.41,14.95) 2.7 0.94 (0.66,1.33) 4.79 (2.98,7.70) 6.6
20 0.76 (0.61,0.95) 3.81 (2.75,5.26) 8.1 2.42 (1.34,4.38) 6.56 (3.54,12.17) 3.5 1.36 (0.91,2.03) 9.39 (6.25,14.11) 9.2
22F 5.42 (3.75,7.83) 13.20 (10.03,17.35) 4.3 5.41 (2.92,10.02) 10.42 (5.36,20.24) 3.6 1.06 (0.78,1.46) 6.27 (4.29,9.17) 11.1
23F 0.84 (0.65,1.07) 3.71 (2.89,4.77) 9.0 1.54 (1.00,2.35) 2.98 (1.68,5.27) 2.8 0.33 (0.22,0.51) 1.89 (1.00,3.59) 11.4
33F 1.39 (1.06,1.82) 8.24 (5.74,11.83) 12.5 2.79 (1.73,4.49) 7.89 (4.73,13.15) 5.3 1.78 (1.17,2.71) 16.18 (11.43,22.91) 12.3
a FR = fold rise from pre to post-vaccination.
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second dose Indigenous participants. However, we did not observe
any effect of gender on the response of each group to 23vPPV,
although for both males and females, non-Indigenous participants
responded highest followed by Indigenous first dose and second
recipients.
It is possible that our a priori requirement for an adequate
response against 12 serotypes may have been too conservative.
Given that the 23vPPV covers 74% of known serotypes in our
Indigenous Australian population [1] with an estimated vaccine
efficacy of 74% against IPD, a response to a larger number of ser-
otypes such as 16 or 21 may be more appropriate. A more stringent
requirement would be in line with the AAAAI definition of an ade-
quate response to 70% or 16 serotypes in adults [25]. Based on
these definitions, indigenous second dose recipients responded
the lowest to 23vPPV. Our rationale for setting an a priori definition
of an adequate immune response considered several factors given
that the protective threshold of serotype-specific IgG in adults, or
following 23vPPV, is unknown. A number of criteria have been
described for normal response to 23vPPV [26–28]. Typically,
immune response to 23vPPV is based on a two-four-fold rise in
serotype-specific IgG and/or a post-immunisation titre 1.3 lg/
ml [29]. Indeed, serotype-specific IgG levels across all groups in
this study were above 1.3 lg/ml. Therefore, analysis based purely
on group IgG GMCs and not on defined criteria to respond to
23vPPV may potentially mask groups of individuals with an inad-
equate response [30]. Our definition therefore required both an
adequate rise in post-vaccination antibody titre and a post-
vaccination antibody titre to be above a critical threshold for a
given number of serotypes, based on data from a limited number
of adult studies [21,31] and expert opinion [16].
A number of limitations were associated with our study. The
sample size was lower than expected, particularly for the second
dose 23vPPV group. Recruitment for this group was stalled for
9 months due to an interim recommendation by the Therapeutic
Goods Administration of Australia advising against the administra-
tion of second or subsequent vaccine doses whilst an investigation
into elevated rates of significant local reactions was undertaken
[32]. The primary definition used in this study was based on AAAAI
guidelines for infants less than 5 years of age (i.e. response to 50%
of serotypes) and was not as sensitive to detect inadequate
response, and so may have masked any true hyporesponse in this
study population.
In light of these findings, the current recommendation of
23vPPV immunisation for Indigenous adults may need reconsider-
ing. Furthermore, strategies to improve 23vPPV uptake within this
population should also be a priority. The licensure of new conju-
gate vaccines (PCV13) for use in older adults may be one way to
improve the magnitude and duration of immunity in this popula-
tion. In the Northern Territory, PCV13 has since replaced 23vPPV
for Indigenous infants at 18 months of age, and should provide
more effective boosting of immunity as well as impact on carriage.
The current issues faced with the use of 23vPPV, especially in high-
risk populations such as those individuals in our study, highlights
the need for a robust vaccination programme in these settings.
6. Conclusion
Taken together, our data has demonstrated a poorer response to
a first dose 23vPPV in Indigenous adults compared to non-
Indigenous adults in Australia, as well as a reduced immune
response for those receiving a second dose 23vPPV compared to
their first dose. Confirmation of the immunogenicity of future pneu-
mococcal vaccine programs is important, particularly for Indige-
nous Australian adults. We propose that in the context of the
current 23vPPV vaccination program in this setting, standardized
and well-recognised definitions of an adequate immune response
such as those by AAAAI be used in conjunction with serotype-
specific IgG GMCs to determine 23vPPV responsiveness in
high-risk settings.
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